We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Walmart, Visa, Novo Nordisk, Village Super Market and Empire Petroleum
Read MoreHide Full Article
For Immediate Release
Chicago, IL – October 14, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Walmart Inc. (WMT - Free Report) , Visa Inc. (V - Free Report) , Novo Nordisk A/S (NVO - Free Report) , Village Super Market, Inc. (VLGEA - Free Report) and Empire Petroleum Corp. (EP - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Analyst Reports for Walmart, Visa and Novo Nordisk
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Walmart Inc., Visa Inc. and Novo Nordisk A/S, as well as two micro-cap stocks Village Super Market, Inc. and Empire Petroleum Corp.. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Walmart's shares have outperformed the Zacks Retail - Supermarkets industry over the past year (+6.3% vs. +5.3%). The company's value positioning and integrated omnichannel model provide a strong foundation for sustained growth. Traffic and market-share gains remain healthy, while e-commerce, marketplace, advertising and membership are expanding the revenue mix and improving digital economics.
International operations and Sam's Club add further diversification. However, elevated operating costs, pharmacy-related sales pressure and heavy capital spending can limit earnings leverage and free-cash-flow conversion.
Continued price reinvestment supports customer loyalty and share gains but may restrain margin expansion, while currency swings can add volatility. While Walmart's fundamentals remain resilient, stronger returns will depend on disciplined execution, productivity gains and successful monetization of its expanding retail ecosystem.
Shares of Visa have outperformed the Zacks Financial Transaction Services industry over the past year (+12.6% vs. -6.5%). The company's scale and brand strength keep it at the center of global digital payments, with growth still driven by higher payment volumes, cross-border activity and rising transaction counts.
Fiscal Q3 2026 results showed broad momentum across consumer payments, commercial and money movement solutions and value-added services. Investments in agentic commerce and stablecoin settlement, along with targeted acquisitions and disciplined capital returns, should continue to enhance the value of its network over time.
However, rising client incentives and marketing expenses are weighing on V's profitability, with adjusted net margin declining to 54.1% in fiscal Q3 2026. Cash activity remains uneven across regions, while the valuation remains elevated and regulatory and litigation risks persist. As such, we have a Neutral rating on the shares.
Novo Nordisk's shares have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-29.6% vs. +30%). That the company raised its 2026 outlook offers limited comfort, as intensifying competition, pricing pressure and higher spending continue to weigh on growth, clouding hopes for a near-term turnaround.
Nevertheless, Novo Nordisk was recently rebranded as Novo. Its semaglutide drugs for obesity and diabetes continue to drive growth through volume gains. Label expansions in other indications will likely boost sales. Higher-dose Wegovy is approved in the EU and the United States, which is a positive.
Novo Nordisk's Wegovy pill secured FDA approval for obesity and has already surpassed five million prescriptions since launch. Wegovy pill is also approved in the EU. The Ozempic pill has also been launched in the U.S. market for diabetes. Partnerships with OpenAI, AWS and Anthropic to boost drug discovery are a positive.
Shares of Village Super Market have outperformed the Zacks Retail - Supermarkets industry over the past year (+37.6% vs. +5.3%). This microcap company with a market capitalization of $650.88 million has seen its fiscal 2026 revenues increase 3.7%, supported by steady same-store sales growth, expanding digital demand and strong fresh-food performance. Robust operating cash flow of $108.8 million provides flexibility to fund expansion, store modernization and consistent dividends.
Planned store openings in fiscal 2027 could drive incremental revenues, while its Wakefern affiliation offers purchasing efficiencies and competitive advantages. Established retail brands, loyalty programs and differentiated merchandising further strengthen customer engagement and market positioning.
However, the company faces pressures from declining gross margins, rising operating expenses and increased promotional spending. Additionally, its heavily unionized workforce and potential pension obligations could increase operating costs. The stock trades at a discount to industry peers on an EV/sales and EV/EBITDA basis.
Empire Petroleum's shares have underperformed the Zacks Oil and Gas - Integrated - United States industry over the past year (-14.9% vs. +43.9%). This microcap company with a market capitalization of $135.21 million has seen persistent liquidity constraints, negative operating cash flow and reliance on external financing. These remain significant concerns, increasing the potential for shareholder dilution.
Declining production, elevated operating costs, commodity-price volatility and limited hedging further complicate the outlook. Moreover, uncertainty surrounding regulatory resolution in New Mexico and execution risks across development projects could delay anticipated benefits.
Nevertheless, Empire Petroleum's long-term growth prospects are supported by its expanding Texas infrastructure, broader development inventory and ongoing efforts to enhance production across multiple regions. Its natural gas development initiatives, Louisiana drilling program and thermal recovery operations in North Dakota provide additional opportunities for production growth and improved operating efficiency.
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
View the Zacks #1 Rank List
Image: Bigstock
The Zacks Analyst Blog Highlights Walmart, Visa, Novo Nordisk, Village Super Market and Empire Petroleum
For Immediate Release
Chicago, IL – October 14, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Walmart Inc. (WMT - Free Report) , Visa Inc. (V - Free Report) , Novo Nordisk A/S (NVO - Free Report) , Village Super Market, Inc. (VLGEA - Free Report) and Empire Petroleum Corp. (EP - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Analyst Reports for Walmart, Visa and Novo Nordisk
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Walmart Inc., Visa Inc. and Novo Nordisk A/S, as well as two micro-cap stocks Village Super Market, Inc. and Empire Petroleum Corp.. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Today's Featured Research Reports
Walmart's shares have outperformed the Zacks Retail - Supermarkets industry over the past year (+6.3% vs. +5.3%). The company's value positioning and integrated omnichannel model provide a strong foundation for sustained growth. Traffic and market-share gains remain healthy, while e-commerce, marketplace, advertising and membership are expanding the revenue mix and improving digital economics.
International operations and Sam's Club add further diversification. However, elevated operating costs, pharmacy-related sales pressure and heavy capital spending can limit earnings leverage and free-cash-flow conversion.
Continued price reinvestment supports customer loyalty and share gains but may restrain margin expansion, while currency swings can add volatility. While Walmart's fundamentals remain resilient, stronger returns will depend on disciplined execution, productivity gains and successful monetization of its expanding retail ecosystem.
(You can read the full research report on Walmart here >>>)
Shares of Visa have outperformed the Zacks Financial Transaction Services industry over the past year (+12.6% vs. -6.5%). The company's scale and brand strength keep it at the center of global digital payments, with growth still driven by higher payment volumes, cross-border activity and rising transaction counts.
Fiscal Q3 2026 results showed broad momentum across consumer payments, commercial and money movement solutions and value-added services. Investments in agentic commerce and stablecoin settlement, along with targeted acquisitions and disciplined capital returns, should continue to enhance the value of its network over time.
However, rising client incentives and marketing expenses are weighing on V's profitability, with adjusted net margin declining to 54.1% in fiscal Q3 2026. Cash activity remains uneven across regions, while the valuation remains elevated and regulatory and litigation risks persist. As such, we have a Neutral rating on the shares.
(You can read the full research report on Visa here >>>)
Novo Nordisk's shares have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-29.6% vs. +30%). That the company raised its 2026 outlook offers limited comfort, as intensifying competition, pricing pressure and higher spending continue to weigh on growth, clouding hopes for a near-term turnaround.
Nevertheless, Novo Nordisk was recently rebranded as Novo. Its semaglutide drugs for obesity and diabetes continue to drive growth through volume gains. Label expansions in other indications will likely boost sales. Higher-dose Wegovy is approved in the EU and the United States, which is a positive.
Novo Nordisk's Wegovy pill secured FDA approval for obesity and has already surpassed five million prescriptions since launch. Wegovy pill is also approved in the EU. The Ozempic pill has also been launched in the U.S. market for diabetes. Partnerships with OpenAI, AWS and Anthropic to boost drug discovery are a positive.
(You can read the full research report on Novo Nordisk here >>>)
Shares of Village Super Market have outperformed the Zacks Retail - Supermarkets industry over the past year (+37.6% vs. +5.3%). This microcap company with a market capitalization of $650.88 million has seen its fiscal 2026 revenues increase 3.7%, supported by steady same-store sales growth, expanding digital demand and strong fresh-food performance. Robust operating cash flow of $108.8 million provides flexibility to fund expansion, store modernization and consistent dividends.
Planned store openings in fiscal 2027 could drive incremental revenues, while its Wakefern affiliation offers purchasing efficiencies and competitive advantages. Established retail brands, loyalty programs and differentiated merchandising further strengthen customer engagement and market positioning.
However, the company faces pressures from declining gross margins, rising operating expenses and increased promotional spending. Additionally, its heavily unionized workforce and potential pension obligations could increase operating costs. The stock trades at a discount to industry peers on an EV/sales and EV/EBITDA basis.
(You can read the full research report on Village Super Market here >>>)
Empire Petroleum's shares have underperformed the Zacks Oil and Gas - Integrated - United States industry over the past year (-14.9% vs. +43.9%). This microcap company with a market capitalization of $135.21 million has seen persistent liquidity constraints, negative operating cash flow and reliance on external financing. These remain significant concerns, increasing the potential for shareholder dilution.
Declining production, elevated operating costs, commodity-price volatility and limited hedging further complicate the outlook. Moreover, uncertainty surrounding regulatory resolution in New Mexico and execution risks across development projects could delay anticipated benefits.
Nevertheless, Empire Petroleum's long-term growth prospects are supported by its expanding Texas infrastructure, broader development inventory and ongoing efforts to enhance production across multiple regions. Its natural gas development initiatives, Louisiana drilling program and thermal recovery operations in North Dakota provide additional opportunities for production growth and improved operating efficiency.
(You can read the full research report on Empire Petroleum here >>>)
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.